Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - ARIAD PHARMACEUTICALS INC | a50314779ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 17, 2012
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
0-21696
|
22-3106987
|
|
(State or other jurisdiction
|
(Commission
|
(I.R.S. Employer
|
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
26 Landsdowne Street, Cambridge, Massachusetts
|
02139
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01
|
Other Events.
|
On June 18, 2012, ARIAD Pharmaceuticals, Inc. issued a press release announcing that updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation, were featured in an oral presentation at the 2012 European Hematology Association (EHA) annual congress on June 17, 2012. These data show that 54 percent of chronic-phase CML patients in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response.
A copy of the press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.
|
ITEM 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit
|
|
|
Number
|
Description
|
|
99.1
|
Press release dated June 18, 2012.
|
The press release contains hypertext links to information on ARIAD’s website. The information on ARIAD’s website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARIAD Pharmaceuticals, Inc.
|
||
|
By:
|
/s/ Edward M. Fitzgerald____
|
|
|
Edward M. Fitzgerald
|
||
|
Executive Vice President, Chief Financial Officer
|
||
Date: June 19, 2012